Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
Genki Plaza Medical Center for Health Care, Tokyo, Japan.
Hypertens Res. 2024 Feb;47(2):487-495. doi: 10.1038/s41440-023-01468-8. Epub 2023 Oct 19.
Obesity with increased high-sensitive cardiac troponin T (hs-cTnT) has been reported to be more likely to progress cardiovascular disease (CVD) events, which suggests that hs-cTnT may identify a "malignant" phenotype of obesity. We classified 3513 hypertensive patients from the Japan Morning Surge-Home Blood Pressure (J-HOP) study into groups based on body mass index (BMI) (normal weight: <25 kg/m, overweight: 25-29.9 kg/m, obesity: ≥30 kg/m) and elevations in biomarker levels (hs-cTnT ≥3 ng/mL: 51.3%, 54.9%, 53.3%, and N-terminal pro-brain natriuretic peptide [NT-ProBNP] ≥55 pg/mL: 51.1%, 40.7%, 36.0% in each BMI category). We evaluated the independent and combined associations of BMI and each hs-cTnT/NT-proBNP or both with CVD events (fatal and nonfatal coronary artery disease, stroke, and hospitalized heart failure). During the mean 6.4 ± 3.9-year follow-up, 232 CVD events occurred. Obesity with elevated hs-cTnT was associated with a risk of CVD events compared to normal weight without elevated hs-cTnT (hazard ratio 3.22, 95% confidence interval: 1.83-5.68). A similar pattern of results was also observed across the status of obesity and elevated NT-proBNP. There was a significant interaction between hs-cTnT and CVD events according to the obesity status (p = 0.039), while this association was marginal in NT-proBNP (p = 0.060). The magnitude of the mediation of hs-cTnT for the association between obesity and CVD risk was 41.2%, and that for NT-proBNP was 8.1%. In this Japanese hypertensive population, the elevation of hs-cTnT identified obese patients at particularly high risk for developing CVD events, suggesting that hs-cTnT may identify a 'malignant' phenotype of obesity.
肥胖伴有高敏心肌肌钙蛋白 T(hs-cTnT)升高已被报道更有可能进展为心血管疾病(CVD)事件,这表明 hs-cTnT 可能识别肥胖的“恶性”表型。我们根据体重指数(BMI)(正常体重:<25kg/m2,超重:25-29.9kg/m2,肥胖:≥30kg/m2)和生物标志物水平升高(hs-cTnT≥3ng/mL:51.3%、54.9%、53.3%,N 末端脑利钠肽前体[NT-ProBNP]≥55pg/mL:51.1%、40.7%、36.0%,在每个 BMI 类别中),将来自日本清晨血压-家庭血压(J-HOP)研究的 3513 例高血压患者分为组。在平均 6.4±3.9 年的随访期间,发生了 232 例 CVD 事件。与正常体重且 hs-cTnT 不升高相比,肥胖且 hs-cTnT 升高与 CVD 事件的风险相关(风险比 3.22,95%置信区间:1.83-5.68)。在肥胖和 NT-proBNP 升高的状态下,也观察到了类似的结果模式。根据肥胖状况,hs-cTnT 与 CVD 事件之间存在显著的相互作用(p=0.039),而 NT-proBNP 则存在边缘相互作用(p=0.060)。hs-cTnT 对肥胖与 CVD 风险之间关联的中介作用幅度为 41.2%,而 NT-proBNP 为 8.1%。在这个日本高血压人群中,hs-cTnT 的升高识别出肥胖患者患 CVD 事件的风险特别高,表明 hs-cTnT 可能识别肥胖的“恶性”表型。